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Sustained Expression of Steroid Receptor Coactivator
SRC-2/TIF-2 is Associated with Better Prognosis in
Malignant Pleural Mesothelioma
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Introduction: Estrogen receptor beta (ER) overexpression by
malignant pleural mesothelioma (MPM) tumor cells correlates with
enhanced patient survival. ER-regulated transcription is mediated by
the p160 family of steroid receptor coactivators (SRCs), and SRC
isoform overexpression is associated with worse prognosis in many
steroid-related malignancies. The aim of this study was to establish
whether SRC isoform expression varied between individual MPM
tumors with positive or negative prognostic significance.
Methods: Immunohistochemical analysis of tumor biopsies from 89
subjects with confirmed histological diagnosis of MPM and biopsies
from 3 normal control subjects was performed to detect the expres-
sion of SRC-1, SRC-2 (TIF-2), SRC-3 (AIB-1), and ER. Allred
scores for expression of ER and each of the SRCs were deter-
mined, and Kaplan-Meier survival curves were calculated to corre-
late biomarker expression, gender, and histology type with postdi-
agnosis survival.
Results: ER and all the SRCs were expressed at high levels in
normal pleural mesothelium, and expression of each biomarker was
reduced or lost in a subset of the MPM subjects; however, postdi-
agnosis survival only significantly correlated with TIF-2 expression.
Low or intermediate expression of TIF-2 correlated with reduced
median postdiagnosis survival (9 months) compared with those
subjects whose tumors highly expressed TIF-2 (20 months) (p 
0.036, log-rank test).
Conclusions: Maintained high expression of TIF-2 in tumor cells
is a positive prognostic indicator for postdiagnosis survival in
patients with confirmed MPM. This is the first clinical study to
correlate high TIF-2 expression with improved patient prognosis
in any malignancy.
Key Words: Mesothelioma, Steroid receptor coactivator, Estrogen
receptor.
(J Thorac Oncol. 2012;7: 243–248)
Malignant pleural mesothelioma (MPM) is a rare buthighly aggressive tumor that arises from the mesothe-
lial surfaces of the pleura.1 A causative link has been estab-
lished between exposure to asbestos fibers and the subsequent
development of MPM in 85% of subjects, while simultaneous
infection with SV40 virus is also believed to contribute to
MPM etiology.2 MPM is often detected decades after initial
exposure to the carcinogen; however, there is also a genetic
contribution that predisposes individuals to developing this
malignancy.3 MPM is invariably terminal, and histological
subtyping is currently the most important prognostic indicator
of postdiagnosis survival time.4 Patients diagnosed with ep-
ithelioid MPM have a mean postdiagnosis survival period of
16.3 months, while patients with sarcomatoid or biphasic
MPM have a poorer prognosis with mean postdiagnosis
survival times of 6.1 and 9.5 months, respectively.5 The
estimation of prognosis based solely on histological typing is
imprecise as up to 70% of all MPM cases are of epithelioid
type, and considerable variation occurs in the actual survival
times for patients within this subgroup. Additional prognostic
markers are required to further subtype MPM cases and so
more effectively refine patient treatment regimes.
Female gender is a positive prognostic factor in MPM
survival,5–7 and this protection is at least partially mediated
through the action of estrogen receptor beta (ER).8
ER-mediated transcription initiation occurs when ligand-
bound ER interacts with gene promoter sequences and re-
cruits steroid receptor coactivators (SRCs) to promote the
formation of the transcription preinitiation complex.9 The
p160 family of coactivator proteins make a rate-limiting
contribution to the formation of this complex and so rigidly
control transcriptional responses stimulated by all steroid
hormones. The p160 family is comprised of steroid receptor
coactivator-1 (SRC-1/NCoA-1),10 transcriptional intermedi-
ary factor 2 (TIF-2/SRC-2/GRIP-1/NCoA-2),11 and amplified
in breast cancer-1 (AIB-1/SRC-3/NCoA-3).12 Dysregulation
of p160 SRC expression affects tumor cell proliferation and
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invasive capacity; this occurs in all steroid-sensitive malig-
nancies including prostate carcinoma13 and endometrial car-
cinoma.12 The contribution of SRCs to tumorigenesis is best
characterized in the context of breast carcinoma where AIB-1
is defined by its upregulation in the most aggressive tumors12
and confirmed by the observation that AIB-1 overexpression
in a mouse model resulted in the spontaneous generation of
mammary tumors.14
The overall effect of estrogen action on tumor cell
biology is complex, particularly in tissues that express both
ER and ER.15 There is growing evidence of a protective
role for ER expression and activation in some malignancies,
including colorectal carcinoma16 and MPM.8 In the context of
colorectal carcinoma, ER is highly expressed by differenti-
ated cells of the colonic epithelium and its expression is lost
in the most aggressive of tumors and correlates with poor
prognosis.16 The dependency of this ER tumor suppressor
effect on differential SRC expression has not been investi-
gated and raises the possibility that in specific, ER-attenu-
ated malignancies, SRCs may also have a tumor-suppressive
role. Indeed, in colon carcinoma, the elevated expression
of AIB-1 correlates with improved patient survival.17
Thus, in contrast with estrogen-stimulated malignancies
such as breast carcinoma or endometrial carcinoma, the
loss of specific SRC expression could diminish the protec-
tive effects exerted by ER and so be a negative prognos-
tic indicator. The aims of this study were to evaluate
expression of SRC-1, TIF-2, and AIB-1 in tumors from a
cohort of patients with confirmed MPM diagnosis using
immunohistochemistry (IHC), to relate SRC expression in
tumor cells to patient survival, and to compare the prog-
nostic efficacy of SRC isoform expression with other
indicative parameters of postdiagnosis survival.
PATIENTS AND METHODS
Patients and Tissue Samples
Eighty-nine confirmed cases of MPM and three control
subjects were identified from the archival pathology files of
the Pathology Unit of the Regional Hospital of Mestre-
Venice, Italy. All diagnoses of MPM were based on World
Health Organization criteria and confirmed in all instances by
clinical, morphological, and IHC data. The tissue samples
were taken after videothoracoscopy biopsy or from resected
surgical specimens. The tissue samples were fixed in neutral
formalin and embedded in paraffin. Permission for tissue to
be used for research purposes was obtained according to local
ethical procedures and following informed patient consent.
Clinical data relating to each of the subjects were obtained
with consent from primary patient records and coded before
analysis by researchers.
Immunohistochemistry
IHC parameters for the ER and p160 SRC family
specific-antibodies were initially optimized using a breast
carcinoma tissue microarray. IHC analysis for each antigen
was performed using a Bond III Automated IHC Stainer
(Leica Microsystems, Wetzlar, Germany) on serial 4-m
depth tissue sections from each of the embedded specimens.
Slides were treated for 20 minutes with Leica BondMax
Epitope Retrieval Solution 1 (ER1) for detection of TIF-2 and
Leica BondMax Epitope Retrieval Solution 2 (ER2) for
detection of SRC-1, AIB-1, and ER to achieve postsection-
ing antigen retrieval. Specific primary antibodies were ap-
plied as indicated: SRC-1 (Clone 128E7, rabbit monoclonal
antibody, 1:200; Cell Signaling Technology, Danvers, MA),
TIF-2 (Clone 29, mouse monoclonal antibody, 1:100; BD
Transduction Laboratories, San Jose, CA), AIB-1 (Clone 34,
mouse monoclonal antibody, 1:200; BD Transduction Labo-
ratories, San Jose, CA), and ER (NCL-ER, mouse mono-
clonal antibody, 1:100; Novocastra, Leica Microsystems,
Ashbourne, Ireland). Primary antibodies were revealed using
the Leica Bond Polymer Refine detection kit, and the signal
was enhanced using the Leica BondMax DAB enhancer kit.
Slides were counterstained with hematoxylin before mount-
ing and microscopic visualization.
Scoring System
Semiquantitative determination of SRC-1, TIF-2,
AIB-1, and ER was performed according to the criteria
described by Allred et al.18 The proportion of positive stained
cells was rated as 0  no cells stained positive, 1  between
0% and 1% positive, 2 between 1% and 10%, 3 between 10%
and 33%, 4 between 33% and 66%, and 5 between 66% and
100%. In addition to the proportion score, an intensity score
was made on the basis of the average intensity of staining:
0  negative, 1  weak, 2  intermediate, and 3  strong.
The proportion score and the intensity score were added to
obtain the total score and is either 0 or between 2 and 8.
Allred scores of 6 or greater were interpreted as strong
staining. Slides were independently evaluated and scored in a
blind fashion by two independent observers. Any discrepan-
cies in scoring between the observers were resolved by
review of the slides under a double-headed microscope, and
a consensus score was allocated.
Statistical Analysis
Differences in postdiagnosis survival were calculated
using Kaplan-Meier analysis, and survival curves were gen-
erated using the TMA Foresight package (TMA Foresight
3.01, Premier Biosoft International, Palo Alto, CA). p values
were calculated using a log-rank test,19 and a p value less than
0.05 was taken to be indicative of statistical significance
between populations. The multivariate Cox proportional haz-
ard regression model was then used to calculate hazard ratios
and to stratify the variables for known clinical parameters.20
This ensures that the prognostic markers are independent of
known clinical parameters (gender, tumor histological type,
age at diagnosis, and chemotherapeutic intervention). All
calculations were performed using the survival library of the
open source R package (http://cran.r-project.org/), and the
two-tailed Wald test was applied.
RESULTS
Patient Cohort Characteristics
SRC isoform and ER expression were determined
using IHC in tumor biopsy specimens for a well-defined
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cohort of MPM subjects with more than 5 years postdiagnosis
follow-up. Paraffin-embedded tumor tissue samples from 89
patients with age range 44 to 82 years (clinicopathological
characteristics shown in Table 1) and 3 normal control
subjects were analyzed. The gender distribution of the MPM
cohort was 73 male and 16 female subjects; the median age
at diagnosis was 64 years for male subjects and 65 years for
female subjects. Histological types were determined to be 71
(79.8%) epithelioid, 10 (11.2%) biphasic, and 8 (9.0%) sar-
comatoid. The majority of the subjects (n  64) had received
cisplatin-based chemotherapy postdiagnosis. Overall, postdi-
agnosis Kaplan-Meier survival curves for histological type
and gender are shown (Figure 1). The median postdiagnosis
survival time was 15 months for patients with epithelioid
MPM, 10 months for subjects with biphasic mesothelioma,
and 6 months for subjects with sarcomatoid mesothelioma
(Figure 1A). The median survival time for male subjects was
10 months and 18 months for female subjects (Figure 1B).
These survival data show that the MPM subjects in this study
have equivalent distribution and outcomes when compared
with MPM subject cohorts from other studies in which
patients with the epithelioid-type mesothelioma have better
prognosis, followed by patients with biphasic mesothelioma,
while patients with sarcomatoid mesothelioma have the worst
prognosis.5,7 Previous studies have also found a gender di-
chotomy in patient outcome, with improved survival for
female MPM patients.5,7,8 Although not statistically signifi-
cant for this cohort (p  0.101, log-rank test), these results in
common with other published studies also indicate that fe-
male MPM subjects have a better prognosis than their male
counterparts.
Normal Pleura and MPM Tissue Tumor
Samples Express SRC-1, TIF-2, and AIB-1
The p160 SRCs are required by all steroid nuclear
receptors including the estrogen receptors to initiate ligand-
dependent transcription.9 The upregulation of SRCs particularly
AIB-1 in the context of breast carcinoma correlates with a more
aggressive tumor phenotype in both estrogen-dependent and
estrogen-independent tumors.14 ER has been proposed as a
tumor suppressor in colorectal carcinoma,21 and its overexpres-
sion in MPM correlates with enhanced patient survival.8 Com-
parative SRC expression in a MPM patient cohort has not been
previously investigated. Herein, we found predominantly nu-
clear staining for each of the p160 SRCs: SRC-1 and AIB-1
(Supplemental Figure 1, http://links.lww.com/JTO/A146),
TIF-2, and also ER (Figure 2) in all three normal pleural
mesothelium tissue samples. All cells making up the normal
mesothelial monolayer stained with high intensity for ER and
each of the SRCs. For the 89 MPM subjects, there was marked
variation in IHC staining intensity and the proportion of posi-
tively stained cells between the tumor specimens from the
different subjects (Figure 2). The Allred scoring system was
applied to quantify staining in each of the tumor samples for the
TABLE 1. Summary of Subject Characteristics at Diagnosis
and p160 SRC Immunohistochemistry Data (n  89)
Male
(n  73)
Female
(n  16)
All
(n  89)
Age at diagnosis, median
(range)
64 (44–82) 65 (55–79) 64 (44–82)
Histology type, n (%)
Epithelioid 56 (76.7) 15 (93.7) 71 (79.8)
Biphasic 9 (12.3) 1 (6.3) 10 (11.2)
Sarcomatoid 8 (11.0) 0 (0) 8 (9.0)
Stage
T2 22 (30.1) 5 (31.2) 27 (30.3)
T3 40 (54.8) 5 (31.2) 45 (50.6)
T4 11 (15.1) 6 (37.5) 17 (19.1)
N0 45 (61.6) 14 (87.5) 59 (66.3)
N1 16 (21.9) 0 (0) 16 (20)
N2 12 (16.4) 2 (12.5) 14 (15.7)
M0 73 (100) 16 (100) 89 (100)
M1 0 (0) 0 (0) 0 (0)
Surgery
Yes 48 (65.75) 11 (68.75) 59 (66.3)
No 25 (34.25) 5 (31.25) 30 (33.7)
SRC, steroid receptor coactivator.
FIGURE 1. Kaplan-Meier survival curves for malignant pleural
mesothelioma subject survival discriminated by histological
type (A) and gender (B).
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three p160 SRCs and ER (Table 2). A predominantly
nuclear staining with Allred score 6 was observed in 39
(43.8%) MPM subjects for SRC-1, 38 (42.7%) subjects for
TIF-2, and 52 (58.4%) subjects for AIB-1. Low or interme-
diate staining (Allred score 5) was observed in 50 cases for
SRC-1 (56.2%), 51 cases for TIF-2 (57.3%), and 37 cases for
AIB-1 (41.6%). ER was also localized to the nuclei of
positively stained cells, and negative ER staining (Allred
score 3) was observed in 23 cases (25.8%).
Kaplan-Meier survival curves were calculated for subjects
with high versus intermediate/low Allred expression scores of
SRC-1 (Supplemental Figure 2, http://links.lww.com/JTO/A147),
TIF-2 (Figure 3A), AIB-1 (Supplementary data), and positive
versus negative ER expression (Figure 4) in the individual
tumor samples. Median postdiagnosis survival for subjects
with high expression of SRC-1 was 14 months, while the
median survival for subjects with intermediate/low expres-
sion was only slightly lower at 10 months. However, median
survival for patients with high expression of TIF-2 was 20
months, while the median survival for patients with interme-
diate/low expression was significantly lower at 9 months,
thus patients with intermediate/low expression of TIF-2
showed a statistically worse outcome compared with patients
with high levels of TIF-2 expression (p  0.036, log-rank
test). Median survival for patients with high or intermediate/
low expression of AIB-1 was 12 months. Median survival of
ER positive patients was 15 months and 8 months for ER
negative patients, but was not statistically significant in this
cohort (p  0.254, log-rank test).
TIF-2 Expression and Prognosis in Epithelioid
and Male-Only Subgroups
Histological type and gender influence postdiagnosis
survival in MPM. Epithelioid histological type is a positive
prognostic factor in MPM, while male gender is a negative
prognostic factor. To determine whether TIF-2 expression
was of prognostic value when the outcome for epithelioid
histology type or male subjects was analyzed separately,
Kaplan-Meier survival curves were calculated for high versus
intermediate/low TIF-2 expression in the tumors of subjects
within these two subgroups. Median survival for subjects
with epithelioid tumors (n 71) that expressed high levels of
TIF-2 was 23 months, while for those subjects with low or
intermediate levels of TIF-2 expression had a median survival
time of 9 months (p  0.031, log-rank test) (Figure 3B).
Median survival of male patients (n  73) with high TIF-2
FIGURE 2. Representative immunohistochemical staining (200 magnification) TIF-2 (A–E) and ER (F–J) in normal pleural
mesothelium (NM) and malignant pleural mesothelioma tumor tissue with Allred score (AS) values of 2, 4, 6, and 8.
TABLE 2. Summary of Subject p160 SRC and ER
Immunohistochemistry Data (n  89)
Male
(n  73)
Female
(n  16)
All
(n  89)
SRC-1 expression
Low/intermediate 42 (57.5%) 8 (50%) 50 (56.2%)
High 31 (42.5%) 8 (50%) 39 (43.8%)
TIF-2 expression
Low/intermediate 44 (60.3%) 7 (43.8%) 51 (57.3%)
High 29 (39.7%) 9 (56.2%) 38 (42.7%)
AIB-1 expression
Low/intermediate 31 (42.5%) 6 (37.5%) 37 (41.6%)
High 42 (57.5%) 10 (62.5%) 52 (58.4%)
ER expression
Negative 19 (26%) 4 (25%) 23 (25.8%)
Positive 54 (74%) 12 (75%) 66 (74.2%)
SRC, steroid receptor coactivator.
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expression levels was 20 months compared with 8 months for
male patients with low or intermediate levels of TIF-2 ex-
pression (p  0.003, log-rank test) (Figure 3C).
Hazard Ratio
Multivariate Cox proportional hazard regression analysis
was performed correcting for gender (male, female); age at
diagnosis (60, 60–69, 70 years); histological type (epithe-
lioid, biphasic, sarcomatoid) and chemotherapeutic intervention
(therapy, no therapy) (Table 3). The adjusted hazard ratio for
high versus low/intermediate TIF-2 expression was 0.526
(0.301–0.918) (p  0.0239, two-sided Wald test).
DISCUSSION
MPM is a slow-developing malignancy with extremely
poor patient outcome and limited availability of molecular
markers to predict survival or therapeutic efficacy. In steroid-
dependent malignancies of the reproductive tissues, overex-
pression of p160 SRC family proteins correlates with a more
aggressive tumor phenotype and worse prognosis.14 The p160
SRCs form the scaffold for the assembly of the transcription
preinitiation complex and as such are key components in the
induction of estrogen-responsive genes. Dysregulation of
p160 SRC action in breast carcinoma through overexpression
and hyperphosphorylation of the coactivators results initially
in amplification of estrogen responses in tumor cells and
subsequently to uncoupling of cell growth from circulatory
estrogen availability, contributing to the switch from endo-
crine-dependent to growth factor-dependent tumor cell pro-
liferation.22 Recent data suggest that unusually MPM cell
FIGURE 4. Kaplan-Meier survival curve for malignant
pleural mesothelioma subject survival discriminated by
positive versus negative/ER expression for the whole sub-
ject cohort.
TABLE 3. Cox Proportional Hazards Model of Overall
Survival (n  89)
TIF-2 Expression N HR (95% CI) pa
Low/intermediate 51 1.00
High expression 38 0.526 (0.301–0.918) 0.0239
a Two-sided Wald test.
HR, hazard ratio; CI, confidence interval.
FIGURE 3. Kaplan-Meier survival curves for malignant
pleural mesothelioma subject survival discriminated by
high versus low/intermediate TIF-2 expression for the
whole subject cohort (A), epithelioid cases only (B), and
male subjects only (C).
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proliferation may be slowed by circulating estrogens rather
than accelerated,8 and consequently the molecular machinery
of ER-regulated transcription is recruited to tumor suppres-
sion rather than promotion. The antitumor action of estrogens
is transduced through ER which regulates the expression of
cell cycle regulators such as cyclin D1.8,23
The strong dependency of ER transcriptional activity
on SRC abundance led to our investigation of p160 SRC
isoform expression in MPM tumors. Our study found that
each of the p160 SRCs investigated, SRC1, TIF-2, and
AIB-1, were highly expressed in normal pleural mesothelium
from malignancy-free subjects, and this novel observation
suggested a role for these cofactors in the normal physiolog-
ical processes of the pleural mesothelium. Each of the SRCs
were also expressed in the majority of the MPM tumor
specimens analyzed; however, Allred immunohistochemical
scoring of SRC expression revealed that there was a declining
trend in the expression of all three SRCs in tumors from
MPM subjects with the shortest postdiagnosis survival time.
The decline in TIF-2 expression correlated most strongly with
reduced postdiagnosis survival, and TIF-2 expression was a
more accurate predictor of outcome than previously identified
indicators of survival (histological type and gender) in this
cohort of MPM subjects. Furthermore, TIF-2 was a better
predictor of postdiagnosis survival within the epithelioid
tumor subjects than in the cohort as a whole, which included
the biphasic and sarcomatoid tumor subjects. The loss of
TIF-2 expression thus identified a subgroup of epithelioid
tumors that were most likely to have reduced postdiagnosis
survival. Whether this discriminates those subjects whose
malignancy is most likely to progress and develop a sarco-
matoid tumor phenotype remains to be established.
ER is implicated as a tumor suppressor not only in
MPM but also in breast,24,25 prostate,26 and colon carcinoma;
however, TIF-2 expression correlates with worse prognosis in
colorectal carcinoma because colonic epithelium also ex-
presses ER that requires the SRCs for its transcriptional
activity.17 In general, ER transduces the proliferative action
of estrogen, particularly in reproductive tissues. As the nor-
mal pleural mesothelium expresses only ER,8 it may be
anticipated that the SRCs participate exclusively in the anti-
tumor actions of ER promoted by circulatory estrogens. The
benefits of ER expression as manifest through slowed tumor
cell growth may subside with the decline in TIF-2 expression
that was observed in MPM subjects with the poorest postdiag-
nosis survival times. In this cohort of patients, ER expression
was a weaker predictor of survival than TIF-2 expression. This
study is the first clinical report of the transcription factor TIF-2
acting in the role of a tumor suppressor and as a potential
signaling intermediate underpinning the positive prognostic ef-
fects of ER expression in MPM.
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